GGrantIndex
← Leaderboards

Thomas H Sisson

University Of Michigan At Ann Arbor

$6,987,602
Attributed
$9,264,668
Total exposure
4
Grants
2
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.3M · FY200725
$2M$1.5M$1M$500K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$9,264,668 · 4

By mechanism

R01$8,597,359 · 3
K08$667,309 · 1

Top collaborators

Most similar at University Of Michigan At Ann Arbor

Same institution · by research overlap

Others in their field

Top investigators on “Plasminogen Activator

Research focus

Plasminogen ActivatorBleomycinCellsMediatingLungPulmonary FibrosisLung InjuryCicatrixFibrosisEpithelial CellsLung DiseasesAlveolarPathogenesisProteinsPlasminogen Activator Inhibitor 1PhenotypeSeveritiesFibroblastsVitronectinFibrogenesisIn VitroAnimal ModelNovel TherapeuticsPathway Interactions

Grant awards (22)

A Novel PAI-1 Function Drives Lung Fibrosis$706,535
R01 · FY2025 · HL · contact PI
A Novel PAI-1 Function Drives Lung Fibrosis$695,226
R01 · FY2024 · HL · contact PI
Oxidized Phospholipids Derived from Apoptotic Pneumocytes Drives Macrophage Activation and Initiates Lung Fibrosis$604,667
R01 · FY2024 · HL
A Novel PAI-1 Function Drives Lung Fibrosis$696,684
R01 · FY2023 · HL · contact PI
Oxidized Phospholipids Derived from Apoptotic Pneumocytes Drives Macrophage Activation and Initiates Lung Fibrosis$617,007
R01 · FY2023 · HL
Oxidized Phospholipids Derived from Apoptotic Pneumocytes Drives Macrophage Activation and Initiates Lung Fibrosis$617,007
R01 · FY2022 · HL
Oxidized Phospholipids Derived from Apoptotic Pneumocytes Drives Macrophage Activation and Initiates Lung Fibrosis$617,007
R01 · FY2021 · HL
Somatomedin B Binding of Plasminogen Activator Inhibitor-1 in Pulmonary Fibrosis$450,793
R01 · FY2018 · HL · contact PI
Somatomedin B Binding of Plasminogen Activator Inhibitor-1 in Pulmonary Fibrosis$450,793
R01 · FY2017 · HL · contact PI
Somatomedin B Binding of Plasminogen Activator Inhibitor-1 in Pulmonary Fibrosis$450,793
R01 · FY2016 · HL · contact PI
Somatomedin B Binding of Plasminogen Activator Inhibitor-1 in Pulmonary Fibrosis$444,030
R01 · FY2015 · HL · contact PI
Somatomedin B Binding of Plasminogen Activator Inhibitor-1 in Pulmonary Fibrosis$457,247
R01 · FY2014 · HL · contact PI
The Anti-protease and Vitronectin-binding Functions of PAI-1 in Lung Fibrosis$356,590
R01 · FY2011 · HL · contact PI
The Anti-protease and Vitronectin-binding Functions of PAI-1 in Lung Fibrosis$357,271
R01 · FY2010 · HL · contact PI
The Anti-protease and Vitronectin-binding Functions of PAI-1 in Lung Fibrosis$357,933
R01 · FY2009 · HL · contact PI
The Anti-protease and Vitronectin-binding Functions of PAI-1 in Lung Fibrosis$358,576
R01 · FY2008 · HL · contact PI
The Anti-protease and Vitronectin-binding Functions of PAI-1 in Lung Fibrosis$359,200
R01 · FY2007 · HL · contact PI
PLASMIN, FIBRIN, AND METALLOPROTEINASES IN LUNG FIBROSIS$133,434
K08 · FY2004 · HL
PLASMIN, FIBRIN, AND METALLOPROTEINASES IN LUNG FIBROSIS$133,448
K08 · FY2003 · HL
PLASMIN, FIBRIN, AND METALLOPROTEINASES IN LUNG FIBROSIS$133,462
K08 · FY2002 · HL
PLASMIN, FIBRIN, AND METALLOPROTEINASES IN LUNG FIBROSIS$133,476
K08 · FY2001 · HL
PLASMIN, FIBRIN, AND METALLOPROTEINASES IN LUNG FIBROSIS$133,489
K08 · FY2000 · HL